GMED Globus Medical Inc Class A

Globus Medical Announces First Surgeries with ExcelsiusGPS® Interbody Solutions

Globus Medical Announces First Surgeries with ExcelsiusGPS® Interbody Solutions

New ExcelsiusGPS® Interbody Solutions module expands system for planning and navigating the entire interbody fusion procedure

AUDUBON, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that Dr. Sheeraz Qureshi (Hospital for Special Surgery, New York, NY) and Dr. Paul Park (University of Michigan, Ann Arbor, MI) were the first surgeons to utilize the ExcelsiusGPS® Interbody Solutions module. Dr. Qureshi performed a robotic navigated transforaminal lumbar interbody (TLIF) fusion and Dr. Park executed a robotic navigated single position lateral interbody fusion procedure, both using the ExcelsiusGPS® robotic navigation system.

Enhanced utility and efficiency further define ExcelsiusGPS® as the leader in spinal robotics. The system delivers best-in-class responsiveness through next generation software, advanced merging capabilities, and faster robotic arm movement. With the use of navigated instruments to target planned interbody trajectories and optimal port or retractor placement, ExcelsiusGPS® Interbody Solutions seamlessly improves surgeon workflow. “I am very excited for the newest evolution of the ExcelsiusGPS® platform,” said Dr. Sheeraz Qureshi. “This update provides advanced solutions for interbody placement using a robotic navigation platform that do not currently exist.”

ExcelsiusGPS® Interbody Solutions is changing what computer-assisted surgery means for surgeons globally. Surgery with ExcelsiusGPS® has evolved from planning and placing pedicle screws to helping surgeons perform robotic navigated TLIF and LLIF procedures from start to finish. Surgeons can now seamlessly navigate disc preparation, trialing, and interbody insertion through a rigid arm-mounted retractor. ExcelsiusGPS® Interbody Solutions allows for fine-tuned interbody planning of implant size and position with exceptional 3D visibility. Visualizing the implant plan while navigating instruments and implants may help surgeons better achieve surgery goals and execute plans, level by level. As Dr. Paul Park remarked, “The advanced planning and ability of the robot to impact surgery beyond screw placement makes Interbody Solutions the next step forward in the evolution of robotic spinal surgery.”

Globus Medical’s ExcelsiusGPS® is designed to enhance the safety, accuracy, and operating room efficiency of spinal surgery. Every day, this revolutionary platform is helping surgeons and hospitals globally provide the best possible treatment options for their patients. Now, the best-in-class robotic navigation system advancing spine surgery just got better with ExcelsiusGPS® Interbody Solutions.

Visit to learn more.

About Globus Medical, Inc.

, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at .

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at . Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:

Brian Kearns

Senior Vice President, Business Development and Investor Relations

Phone: (610) 930-1800

Email:

EN
12/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Globus Medical Inc Class A

 PRESS RELEASE

Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Re...

Globus Medical Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call AUDUBON, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full-year ended December 31, 2025 after the market close on Tuesday, February 24, 2026. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Parti...

 PRESS RELEASE

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year...

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025. The company anticipates fourth quarter 2025 sales of approximately $823.2 million, an increase of 25.2 percent over the fourth quarter 2024 on an as-reported basis. Full year 2025 sales are expected to be approximately $2.936 billion, an increase of 16.5 percent over ...

Globus Medical Inc: 1 director

A director at Globus Medical Inc sold 4,000 shares at 88.850USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

 PRESS RELEASE

Globus Medical Reports Third Quarter 2025 Results

Globus Medical Reports Third Quarter 2025 Results AUDUBON, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2025. Worldwide net sales were $769.0 million, an increase of 22.9%, or an increase of 22.3% on a constant currency basisBase business, excluding Nevro, net sales were $669.8 million, an increase of 7.0%, or an increase of 6.5% on a constant currency basisGAAP net income for the quarter was $119.0 millionGAAP diluted earnings per share (“EP...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch